The representatives’ letter only explicitly mentions the closure of the Bray site in Ireland and the subsequent transfer of production – “which is a transnational issue” – stresses the letter, where they “regret not having been informed in due time.” This letter mostly points to the concern of European staff representatives in the face of the ongoing merger with Merck. Indeed, on March 9, the American company became second pharmaceutical company in the world, after buying Schering-Plough for $41.1 billion. The operation, effective on the fourth quarter of 2009, is a “reversed merger” after which Schering-Plough, renamed “Merck,” will keep its stock quote, out of respect for agreements signed before the merger.
ional issue” – stresses the letter, where they “regret not having been informed in due time.” This letter mostly points to the concern of European staff representatives in the face of the ongoing merger with Merck. Indeed, on March 9, the American company became second pharmaceutical company in the world, after buying Schering-Plough for $41.1 billion. The operation, effective on the fourth quarter of 2009, is a “reversed merger” after which Schering-Plough, renamed “Merck,” will keep its stock
…Do you have information to share with us?